AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NovaBay Pharmaceuticals, Inc.

$0.89 -$0.35 (-27.97%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$0.86
Day Range
$0.87$0.92
Year Range
$0.83$2.13
Market Cap
45.06M
AVG Volume
835.75K
Trailing/Forward PE
0.06/-
PEG ratio
0
Dividend Yield
447.83%
Next Earnings Date
2026-11-05
Primary Exchange
New York Stock Exchange ArcaUS
Revenue (USD)
-1M01M2M3M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q22.21M
26 Q12.46M
25 Q4-521K
25 Q3521K
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
Net Income (USD)
-200M0200M400M600M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-41.07M
26 Q1552.4M
25 Q4-26.6M
25 Q3-1.29M
25 Q2-1.92M
25 Q1-3.53M
24 Q4-1.21M
24 Q3-1.21M
24 Q2-1.58M
24 Q1-3.21M
Operating Income (USD)
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-3.21M
26 Q1-385K
25 Q4-1.82M
25 Q3-1.17M
25 Q2-1.89M
25 Q1-2.7M
24 Q4-1.77M
24 Q3-1.7M
24 Q2-1.62M
24 Q1-2.29M
EBITDA (USD)
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-3.21M
26 Q1-385K
25 Q4-1.81M
25 Q3-1.14M
25 Q2-1.85M
25 Q1-2.65M
24 Q4-1.71M
24 Q3-1.62M
24 Q2-1.52M
24 Q1-2.19M
Cash Flows (USD)
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-5.96M
26 Q1-1.8M
25 Q4-2.27M
25 Q3-1.84M
25 Q2-2.99M
25 Q1-1.32M
24 Q4-1.56M
24 Q3-2.44M
24 Q2-1.51M
24 Q1-1.98M
EPS (USD)
-150-100-5005024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-1.32
26 Q13.33
25 Q4-4.57
25 Q3-1.1
25 Q2-1.65
25 Q1-3.33
24 Q4-1.24
24 Q3-9.6
24 Q2-6.86
24 Q1-149.75
Expenses (USD)
-2M02M4M6MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q25.42M
26 Q12.85M
25 Q41.74M
25 Q31.21M
25 Q21.85M
25 Q12.65M
24 Q41.71M
24 Q31.62M
24 Q21.53M
24 Q12.22M
Cash & Debt (USD)
05M10M15M20MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q26.97M
26 Q118.41M
25 Q47.96M
25 Q32.31M
25 Q25.48M
25 Q18.6M
24 Q4430K
24 Q3776K
24 Q2751K
24 Q11.82M
Debt ratios
-10123424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Debt ratios by quarter
PeriodDebt ratios
26 Q21.07
26 Q13.43
25 Q40.96
25 Q30.18
25 Q20.57
25 Q11
24 Q4-0.18
24 Q3-0.08
24 Q2-0.24
24 Q1-0.12
Margins
0%25%50%75%100%22 Q322 Q423 Q123 Q223 Q323 Q425 Q325 Q426 Q126 Q2
SDEV Margins by quarter
PeriodMargins
26 Q2100%
26 Q1100%
25 Q417.08%
25 Q38.06%
23 Q451.55%
23 Q366.99%
23 Q249.21%
23 Q168.41%
22 Q448.17%
22 Q362.08%
Return on Capital
-3000%-2000%-1000%0%1000%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Return on Capital by quarter
PeriodReturn on Capital
26 Q2-32.28%
26 Q1397.91%
25 Q4116.52%
25 Q3-79.13%
25 Q2-45.28%
25 Q1-57.24%
24 Q4939.53%
24 Q3-113.06%
24 Q2256.89%
24 Q1-2008.75%
Shares Outstanding
010M20M30M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Shares Outstanding by quarter
PeriodShares Outstanding
26 Q231.05M
26 Q126.02M
25 Q45.82M
25 Q31.18M
25 Q21.16M
25 Q11.06M
24 Q4977K
24 Q3231K
24 Q2231K
24 Q124K
Dividends (USD)
0246Sep 25
SDEV Dividends (USD) by quarter
PeriodDividends (USD)
Sep 254
Book Value Per Share (USD)
-5051024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q24.1
26 Q15.34
25 Q4-3.92
25 Q31.39
25 Q23.65
25 Q15.81
24 Q4-0.13
24 Q34.64
24 Q2-2.67
24 Q16.67
Total Assets (USD)
050M100M150M200M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SDEV Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q2127.51M
26 Q1179.74M
25 Q410.65M
25 Q33.49M
25 Q26.91M
25 Q19.87M
24 Q445.91M
24 Q33.88M
24 Q23.92M
24 Q15.36M
PE Ratio
0.040.050.060.07med 0.06Jun 26Jul 26Jul 26Aug 26Sep 26
SDEV PE Ratio by quarter
PeriodPE Ratio
Sep 260.06
Sep 260.06
Aug 260.05
Aug 260.06
Aug 260.05
Aug 260.05
Jul 260.06
Jul 260.05
Jul 260.06
Jul 260.07
Jul 260.07
Jun 260.06
Jun 260.06
Jun 260.05
Jun 260.06
Free Cash Flow Yield
-125%-100%-75%-50%-25%med -42.85%Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
SDEV Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-42.85%
Sep 26-43.01%
Aug 26-36.65%
Aug 26-30.04%
Aug 26-33.25%
Aug 26-33.25%
Jul 26-29.78%
Jul 26-31.14%
Jul 26-27.4%
Jul 26-25.75%
Jul 26-25.18%
Jun 26-30.86%
Jun 26-28.07%
Jun 26-33.91%
Jun 26-30.58%
May 26-114.05%
May 26-102.73%
May 26-88.32%
May 26-88.86%
May 26-110.57%
Apr 26-108.91%
Apr 26-94.06%
Apr 26-90.53%
Apr 26-74.28%
Mar 26-96.56%
Mar 26-124.87%
Mar 26-119.71%
Price to Sales
57.51012.515med 11.72Jun 26Jul 26Jul 26Aug 26Sep 26
SDEV Price to Sales by quarter
PeriodPrice to Sales
Sep 265.94
Sep 265.92
Aug 269.87
Aug 2612.04
Aug 2610.88
Aug 2610.88
Jul 2612.15
Jul 2611.62
Jul 2613.2
Jul 2614.05
Jul 2614.36
Jun 2611.72
Jun 2612.89
Jun 2610.67
Jun 2611.83
Price to Book
0.160.180.20.220.240.26med 0.21Jun 26Jul 26Jul 26Aug 26Sep 26
SDEV Price to Book by quarter
PeriodPrice to Book
Sep 260.22
Sep 260.22
Aug 260.18
Aug 260.21
Aug 260.19
Aug 260.19
Jul 260.22
Jul 260.21
Jul 260.23
Jul 260.25
Jul 260.25
Jun 260.21
Jun 260.23
Jun 260.19
Jun 260.21
NovaBay Pharmaceuticals, Inc.
SDEV
Stockpicker

Video analysis: SDEV

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SDEV

Stablecoin Development (NYSEAMERICAN:SDEV) Stock Price Passes Below 200 Day Moving Average   – What’s Next?

defenseworld.net · 15 Aug 2026

Stablecoin Development (NYSEAMERICAN:SDEV) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Stablecoin Development Corporation (NYSEAMERICAN:SDEV - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.93 and traded as low as $1.01. Stablecoin Development shares last traded at $1.03, with a volume of 75,165 shares. Stablecoin Development

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

globenewswire.com · 3 Aug 2026

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

Abbott Cooper PLLC is investigating fiduciary duty claims for SDEV (formerly NovaBay Pharmaceuticals) holders who owned shares before August 19, 2025.

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

globenewswire.com · 31 Jul 2026

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026  SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated all remaining warrant liabilities from its balance sheet WEST PALM BEACH, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- Stablecoin Development Corporation (NYSE American: SDEV) (the “Company” or “SDEV”), an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems and providing public market access to the stablecoin economy, yesterday reported financial results for the second quarter and first half ended June 30, 2026.

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

globenewswire.com · 17 Jun 2026

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Stablecoin Development Corporation (Nasdaq: SDEV) (formerly NovaBay Pharmaceuticals, Inc.) who held their shares prior to August 19, 2025.

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.